Revelation Pharma

The Revelation Pharma family has been busy helping the holiday joy get to the people who most need it.

The folks at Eastern States Compounding Pharmacy in New Hampshire, Pharmacy Specialists Compounding Pharmacy in Florida, and Lee Silsby Pharmacy in Ohio collected a ton of canned and dry food for their local food banks, while Innovation Compounding in Georgia and Rock Valley Compounding Pharmacy in Illinois gave Santa a boost through Toys for Tots.

The double whammy of goodwill is their way of helping making sure that as many people in their communities have a fuller belly and a bigger smile.

Did we say “double whammy”? It’s even more — a triple whammy. The good folks at Community Clinical Pharmacy in Mesa took some time to raise money for their local animal shelter, ’cause even our four-legged friends appreciate a little extra love.

It’s a season

Revelation Pharma launches PGY1 residency program focused on pharmacy compounding

KENNESAW, Georgia – REVELATION PHARMA, a national network of 503A and 503B compounding pharmacies, is thrilled to announce the launch of its PGY1 residency program for fourth-year pharmacy students.

Offered through Innovation Compounding in Kennesaw, Georgia, the year-long residency will provide critical training and resources for P4 pharmacy students looking to pursue a career in compounding pharmacy.

Compounding is unique as it straddles the origins of the pharmacy profession as well as its future in personalized medicine. Revelation Pharma's PGY1 residency program is the perfect opportunity for pharmacy students who are interested in the core values of pharmacy and who want to focus on patients

Some important updates regarding quality standards and changes to the United States Pharmacopeia (USP) standards are coming that may impact your practice.

To give some background, pharmacies in the Revelation Pharma Network follow standard operating procedures that are built around processes developed by USP. While USP is not a regulatory agency and does not carry the force of law, many state boards of pharmacy as well as the FDA recognize USP’s compounding standards as the measure of quality assurance that a compounding pharmacy should follow.

On November 1, 2023, new editions of USP chapters pertaining to nonsterile, sterile, and hazardous drug compounding will become compendially applicable, meaning that they are the most current versions and regulatory agencies may choose to adopt them.

It is important to note that these new editions are not simple modifications but are largely complete re-writes of the current chapters and represent significant